Mesotelioma

  1. Terán, E. 1
  2. Claros, J. 1
  3. Bellido, L. 1
  4. Del Barco, E. 1
  5. Cigarral, B. 1
  6. Escalera, E. 1
  7. Barrios, B. 1
  8. Casado, D. 1
  9. Figuero, L. 1
  10. Olivares, A. 1
  11. López, A. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1402-1408

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.005 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El mesotelioma es una neoplasia insidiosa que surge de las superficies mesoteliales de las cavidades pleurales. La causa predominante del mesotelioma maligno es la exposición al asbesto por inhalación. El diagnóstico del mesotelioma pleural maligno se establece por características morfológicas e inmunohistoquímicas de una muestra citológica o quirúrgica. La evaluación inicial se acompaña de tomografía computarizada (TC) de tórax con contraste, toracocentesis del derrame pleural existente y la tomografía por emisión de positrones (PET) en la evaluación de ganglios linfáticos mediastínicos. En casos de enfermedad localizada, la cirugía se combina con radioterapia para mejorar el control local de la enfermedad y quimioterapia para reducir el riesgo de recurrencia local y metástasis sistémicas. La combinación de quimioterapia según el esquema cisplatino-pemetrexed se ha convertido en el régimen más ampliamente utilizado en pacientes con mesotelioma pleural maligno irresecable.

Referencias bibliográficas

  • Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17:525-34.
  • Price B. Analysis of current trends in United States mesothelioma inci-dence. Am J Epidemiol. 1997;145:211-8.
  • Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34:718-21.
  • Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980;46:2736-40.
  • Hansen J, de Klerk NH, Musk AW, Hobbs MS. Environmental exposure to crocidolite and mesothelioma: exposure-response rela-tionships. Am J Respir Crit Care Med. 1998;157:69-75.
  • Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hod-gkin lymphoma. Cancer. 2006;107:108-15.
  • Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109:1432-8.
  • Ji J, Sundquist J, Sundquist K. Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study. Eur Respir J. 2016; 48:873-9.
  • Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malig-nant mesothelioma. J Clin Oncol. 2018;36:2863-71.
  • Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax.1999;54(7):638-52.
  • Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nu-clear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-72.
  • Ray M, Kindler HL. Malignant pleural mesothelioma: an update on bio-markers and treatment. Chest. 2009;136:888-6.
  • Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: Ame-rican Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1343-73.
  • Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142:89-108.
  • Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cis-platin followed by extrapleural pneumonectomy and radiation for malig-nant pleural mesothelioma. J Clin Oncol. 2009;27:3007-13.
  • Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giac-cone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experien-ce. J Clin Oncol. 1998;16:145-52.
  • Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol. 2005;23(1):184-9. doi: 10.1200/JCO.2005.07.050
  • Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007;25:5770-6.
  • Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
  • Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405-14.
  • Dudek AZ, Wang XF, Gu L, Stinchcombe T, Kratzke RA, Vokes EE, et al. Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). J Clin Oncol. 2019;37(15):8517.
  • Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemo-naïve patients with malignant pleural mesothelioma: results of the Inter-national Expanded Access Program. J Thorac Oncol. 2008;3:756-63.
  • Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30:2509-15.
  • Scherpereel A, Mazieres J, Greillier L, Dô P, Bylicki O, Monnet I, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol. 2017;35(18)Suppl: LBA8507-LBA8507.
  • Alley EW, López J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Cli-nical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623-30.
  • Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O’Brien M, Pope A, et al. A multicentre randomized phase III trial comparing pembrolizumab (P) versus single-agent chemotherapy (CT) for advanced pretreated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2019; 30Suppl5:v931
Fuente de los datos: Dialnet